|
1
|
Czarnecka AM, Szczylik C and Rini B: The
use of sunitinib in renal cell carcinoma: Where are we now? Expert
Rev Anticancer Ther. 14:983–999. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wood LS: Renal cell carcinoma: Screening,
diagnosis, and prognosis. Clin J Oncol Nurs. 13(Suppl): 3–7. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molina AM, Lin X, Korytowsky B, Matczak E,
Lechuga MJ, Wiltshire R and Motzer RJ: Sunitinib objective response
in metastatic renal cell carcinoma: Analysis of 1059 patients
treated on clinical trials. Eur J Cancer. 50:351–358. 2014.
View Article : Google Scholar
|
|
7
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E,
et al: Final results from the large sunitinib global
expanded-access trial in metastatic renal cell carcinoma. Br J
Cancer. 113:12–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jung YS, Lee SJ, Yoon MH, Ha NC and Park
BJ: Estrogen receptor α is a novel target of the Von Hippel-Lindau
protein and is responsible for the proliferation of VHL-deficient
cells under hypoxic conditions. Cell Cycle. 11:4462–4473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Danilin S, Sourbier C, Thomas L, Rothhut
S, Lindner V, Helwig JJ, Jacqmin D, Lang H and Massfelder T: von
Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of
the survival factor parathyroid hormone-related protein in human
renal cell carcinoma by the RNA-binding protein HuR.
Carcinogenesis. 30:387–396. 2009. View Article : Google Scholar
|
|
10
|
Buczek M, Escudier B, Bartnik E, Szczylik
C and Czarnecka A: Resistance to tyrosine kinase inhibitors in
clear cell renal cell carcinoma: From the patient's bed to
molecular mechanisms. Biochim Biophys Acta. 1845:31–41. 2014.
|
|
11
|
Kornakiewicz A, Solarek W, Bielecka ZF,
Lian F, Szczylik C and Czarnecka AM: Mammalian target of rapamycin
inhibitors resistance mechanisms in clear cell renal cell
carcinoma. Curr Signal Transduct Ther. 8:210–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Concolino G, Marocchi A, Conti C, Tenaglia
R, Di Silverio F and Bracci U: Human renal cell carcinoma as a
hormone-dependent tumor. Cancer Res. 38:4340–4344. 1978.PubMed/NCBI
|
|
13
|
McDonald MW, Diokno AC, Seski JC and Menon
KM: Measurement of progesterone receptor in human renal cell
carcinoma and normal renal tissue. J Surg Oncol. 22:164–166. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Concolino G, Di Silverio F, Marocchi A and
Bracci U: Renal cancer steroid receptors: Biochemical basis for
endocrine therapy. Eur Urol. 5:90–93. 1979.PubMed/NCBI
|
|
15
|
Concolino G, Di Silverio F, Marocchi A and
Bracci U: Renal cancer steroid receptors: Biochemical basis for
endocrine therapy. Eur Urol. 5:319–322. 1979.PubMed/NCBI
|
|
16
|
Jang JH, Min KJ, Kim S, Park JW and Kwon
TK: RU486 induces pro-apoptotic endoplasmic reticulum stress
through the induction of CHOP expression by enhancing C/EBPdelta
expression in human renal carcinoma Caki cells. J Cell Biochem.
117:361–369. 2015. View Article : Google Scholar
|
|
17
|
Zucchetto A, Talamini R, Dal Maso L, Negri
E, Polesel J, Ramazzotti V, Montella M, Canzonieri V, Serraino D,
La Vecchia C, et al: Reproductive, menstrual, and other
hormone-related factors and risk of renal cell cancer. Int J
Cancer. 123:2213–2216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kabat GC, Silvera SA, Miller AB and Rohan
TE: A cohort study of reproductive and hormonal factors and renal
cell cancer risk in women. Br J Cancer. 96:845–849. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qu Y, Chen H, Gu W, Gu C, Zhang H, Xu J,
Zhu Y and D: Age-dependent association between sex and renal cell
carcinoma mortality: A population-based analysis. Sci Rep.
5:91602015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dunzendorfer U, Drahovsky D and
Schmidt-Gayk H: Peptide hormones LH, FSH, TSH, prolactin, beta-HCG
and PTH in patients with urogenital tumors. Onkologie. 4:188–192.
1981.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aguilar-Rojas A and Huerta-Reyes M: Human
gonadotropin-releasing hormone receptor-activated cellular
functions and signaling pathways in extra-pituitary tissues and
cancer cells (Review). Oncol Rep. 22:981–990. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guillermet-Guibert J, Lahlou H, Cordelier
P, Bousquet C, Pyronnet S and Susini C: Physiology of somatostatin
receptors. J Endocrinol Invest. 28(Suppl Int): 5–9. 2005.
|
|
23
|
Lu HT, Salamon H and Horuk R: The biology
and physiology of somatostatin receptors. Expert Opin Ther Targets.
5:613–623. 2001. View Article : Google Scholar
|
|
24
|
Agouni A, Sourbier C, Danilin S, Rothhut
S, Lindner V, Jacqmin D, Helwig JJ, Lang H and Massfelder T:
Parathyroid hormone-related protein induces cell survival in human
renal cell carcinoma through the PI3K Akt pathway: Evidence for a
critical role for integrin-linked kinase and nuclear factor kappa
B. Carcinogenesis. 28:1893–1901. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Riesenbeck LM, Bierer S, Hoffmeister I,
Köpke T, Papavassilis P, Hertle L, Thielen B and Herrmann E:
Hypothyroidism correlates with a better prognosis in metastatic
renal cancer patients treated with sorafenib or sunitinib. World J
Urol. 29:807–813. 2011. View Article : Google Scholar
|
|
26
|
Baldazzi V, Tassi R, Lapini A, Santomaggio
C, Carini M and Mazzanti R: The impact of sunitinib-induced
hypothyroidism on progression-free survival of metastatic renal
cancer patients: A prospective single-center study. Urol Oncol.
30:704–710. 2012. View Article : Google Scholar
|
|
27
|
Liao H, Zhou Q, Gu Y, Duan T and Feng Y:
Luteinizing hormone facilitates angiogenesis in ovarian epithelial
tumor cells and metformin inhibits the effect through the mTOR
signaling pathway. Oncol Rep. 27:1873–1878. 2012.PubMed/NCBI
|
|
28
|
Schmidinger M, Vogl UM, Bojic M, Lamm W,
Heinzl H, Haitel A, Clodi M, Kramer G and Zielinski CC:
Hypothyroidism in patients with renal cell carcinoma: Blessing or
curse? Cancer. 117:534–544. 2011. View Article : Google Scholar
|
|
29
|
Dunzendorfer U, Drahovsky D, Schmidt-Gayk
H and Zahradnik HP: Clinical significance of peptide hormones LH,
FSH, TSH, prolactin, HCG, parathormone, calcitonin and
prostaglandin F2 alpha in kidney neoplasms. Z Urol Nephrol.
74:13–19. 1981.(In German). PubMed/NCBI
|
|
30
|
Siraj MA, Pichon C, Radu A and Ghinea N:
Endothelial follicle stimulating hormone receptor in primary kidney
cancer correlates with subsequent response to sunitinib. J Cell Mol
Med. 16:2010–2016. 2012. View Article : Google Scholar
|
|
31
|
Schally AV and Varga JL: Antagonistic
analogs of growth Hormone-releasing hormone: New potential
antitumor agents. Trends Endocrinol Metab. 10:383–391. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schally AV, Varga JL and Engel JB:
Antagonists of growth-hormone-releasing hormone: An emerging new
therapy for cancer. Nat Clin Pract Endocrinol Metab. 4:33–43. 2008.
View Article : Google Scholar
|
|
33
|
Jungwirth A, Schally AV, Pinski J, Groot
K, Armatis P and Halmos G: Growth hormone-releasing hormone
antagonist MZ-4–71 inhibits in vivo proliferation of Caki-I renal
adenocarcinoma. Proc Natl Acad Sci USA. 94:5810–5813. 1997.
View Article : Google Scholar
|
|
34
|
Halmos G, Schally AV, Varga JL, Plonowski
A, Rekasi Z and Czompoly T: Human renal cell carcinoma expresses
distinct binding sites for growth hormone-releasing hormone. Proc
Natl Acad Sci USA. 97:10555–10560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rick F, Szalontay L, Abi-Chaker A, Block
NL, Halmos G and Schally AV: Effect of novel growth
hormone-releasing hormone antagonists on growth of experimental
renal cell carcinomas. J Clin Oncol. 31:abstr 469. 2013.
|
|
36
|
Vikić-Topić S, Raisch KP, Kvols LK and
Vuk-Pavlović S: Expression of somatostatin receptor subtypes in
breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin
Endocrinol Metab. 80:2974–2979. 1995.
|
|
37
|
Turman MA and Apple CA: Human proximal
tubular epithelial cells express somatostatin: Regulation by growth
factors and cAMP. Am J Physiol. 274:F1095–F1101. 1998.PubMed/NCBI
|
|
38
|
Freudenberg LS, Gauler T, Görges R, Bauer
S, Stergar H, Antoch G, Bockisch A and Schütte J: Somatostatin
receptor scintigraphy in advanced renal cell carcinoma. Results of
a phase II-trial of somatostatine analogue therapy in patients with
advanced RCC. Nuklearmedizin. 47:127–131. 2008.PubMed/NCBI
|
|
39
|
Tezval H, Jurk S, Atschekzei F, Becker JU,
Jahn O, Serth J and Kuczyk MA: Urocortin and
corticotropin-releasing factor receptor 2 in human renal cell
carcinoma: Disruption of an endogenous inhibitor of angiogenesis
and proliferation. World J Urol. 27:825–830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tezval H, Atschekzei F, Peters I, Waalkes
S, Hennenlotter J, Stenzl A, Becker JU, Merseburger AS, Kuczyk MA
and Serth J: Reduced mRNA expression level of
corticotropin-releasing hormone-binding protein is associated with
aggressive human kidney cancer. BMC Cancer. 13:1992013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thwaites DT, Hirst BH and Simmons NL:
Passive transepithelial absorption of thyrotropin-releasing hormone
(TRH) via a para-cellular route in cultured intestinal and renal
epithelial cell lines. Pharm Res. 10:674–681. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arai E, Chiku S, Mori T, Gotoh M, Nakagawa
T, Fujimoto H and Kanai Y: Single-CpG-resolution methylome analysis
identifies clinicopathologically aggressive CpG island methylator
phenotype clear cell renal cell carcinomas. Carcinogenesis.
33:1487–1493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Keller G, Schally AV, Gaiser T, Nagy A,
Baker B, Halmos G and Engel JB: Receptors for luteinizing hormone
releasing hormone expressed on human renal cell carcinomas can be
used for targeted chemotherapy with cytotoxic luteinizing hormone
releasing hormone analogues. Clin Cancer Res. 11:5549–5557. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Engel J, Emons G, Pinski J and Schally AV:
AEZS-108: A targeted cytotoxic analog of LHRH for the treatment of
cancers positive for LHRH receptors. Expert Opin Investig Drugs.
21:891–899. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jungwirth A, Schally AV, Halmos G, Groot
K, Szepeshazi K, Pinski J and Armatis P: Inhibition of the growth
of Caki-I human renal adenocarcinoma in vivo by luteinizing
hormone-releasing hormone antagonist Cetrorelix, somatostatin
analog RC-160, and bombesin antagonist RC-3940-II. Cancer.
82:909–917. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Choi JW, Park SC, Kang GH, Liu JO and Youn
HD: Nur77 activated by hypoxia-inducible factor-1alpha overproduces
proopiomelanocortin in von Hippel-Lindau-mutated renal cell
carcinoma. Cancer Res. 64:35–39. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Waters MJ: The growth hormone receptor.
Growth Horm IGF Res. Jun 7–2015. View Article : Google Scholar : (Epub ahead of
print). PubMed/NCBI
|
|
48
|
Gan Y, Buckels A, Liu Y, Zhang Y, Paterson
AJ, Jiang J, Zinn KR and Frank SJ: Human GH receptor-IGF-1 receptor
interaction: Implications for GH signaling. Mol Endocrinol.
28:1841–1854. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sekizawa N, Hayakawa E, Tsuchiya K,
Yoshimoto T, Akashi T, Fujii T, Yamada S and Hirata Y: Acromegaly
associated with multiple tumors. Intern Med. 48:1273–1278. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Asai K, Shimoyama S, Sanno N, Kaminishi M
and Oohara T: A rare case of gastric cancer in an acromegalic
patient. J Gastroenterol. 32:528–532. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Prinzi N, Sorrenti S, Baldini E, De Vito
C, Tuccilli C, Catania A, Coccaro C, Bianchini M, Nesca A, Grani G,
et al: Association of thyroid diseases with primary extra-thyroidal
malignancies in women: Results of a cross-sectional study of 6,386
patients. PLoS One. 10:e01229582015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bailey EB, Tantravahi SK, Poole A, Agarwal
AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD and
Agarwal N: Correlation of degree of hypothyroidism with survival
outcomes in patients with metastatic renal cell carcinoma receiving
vascular endothelial growth factor receptor tyrosine kinase
inhibitors. Clin Genitourin Cancer. 13:e131–e137. 2015. View Article : Google Scholar
|
|
53
|
Nearchou A, Valachis A, Lind P, Akre O and
Sandström P: Acquired hypothyroidism as a predictive marker of
outcome in patients with metastatic rmenal cell carcinoma treated
with tyrosine kinase inhibitors: A literature-based meta-analysis.
Clin Genitourin Cancer. 13:280–286. 2015. View Article : Google Scholar
|
|
54
|
Siraj A, Desestret V, Antoine M, Fromont
G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, Gonin J, et
al: Expression of follicle-stimulating hormone receptor by the
vascular endothelium in tumor metastases. BMC Cancer. 13:2462013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Radu A, Pichon C, Camparo P, Antoine M,
Allory Y, Couvelard A, Fromont G, Hai MT and Ghinea N: Expression
of follicle-stimulating hormone receptor in tumor blood vessels. N
Engl J Med. 363:1621–1630. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gartrell BA, Tsao CK and Galsky MD: The
follicle-stimulating hormone receptor: A novel target in
genitourinary malignancies. Urol Oncol. 31:1403–1407. 2013.
View Article : Google Scholar
|
|
57
|
Alam H, Weck J, Maizels E, Park Y, Lee EJ,
Ashcroft M and Hunzicker-Dunn M: Role of the
phosphatidylinositol-3-kinase and extracellular regulated kinase
pathways in the induction of hypoxia-inducible factor (HIF)-1
activity and the HIF-1 target vascular endothelial growth factor in
ovarian granulosa cells in response to follicle-stimulating
hormone. Endocrinology. 150:915–928. 2009. View Article : Google Scholar :
|
|
58
|
Stanisic TH and Donovan J: Prolactin
secreting renal cell carcinoma. J Urol. 136:85–86. 1986.PubMed/NCBI
|
|
59
|
Yakirevich E, Matoso A, Morris D and
Resnick M: Steroid receptors in renal cell carcinoma. Emerging
Research and Treatments in Renal Cell Carcinoma. Amato RJ: InTech;
Rijeka, Croatia: 2012, View
Article : Google Scholar
|
|
60
|
Iwai A, Fujii Y, Kawakami S, Takazawa R,
Kageyama Y, Yoshida MA and Kihara K: Down-regulation of vascular
endothelial growth factor in renal cell carcinoma cells by
glucocorticoids. Mol Cell Endocrinol. 226:11–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yakirevich E, Matoso A, Sabo E, Wang LJ,
Tavares R, Meitner P, Morris DJ, Pareek G, Delellis RA and Resnick
MB: Expression of the glucocorticoid receptor in renal cell
neoplasms: An immunohistochemical and quantitative reverse
transcriptase polymerase chain reaction study. Hum Pathol.
42:1684–1692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Min KJ, Jang JH, Lee JT, Choi KS and Kwon
TK: Glucocorticoid receptor antagonist sensitizes TRAIL-induced
apoptosis in renal carcinoma cells through up-regulation of DR5 and
down-regulation of c-FLIP(L) and Bcl-2. J Mol Med Berl. 90:309–319.
2012. View Article : Google Scholar
|
|
63
|
Bojar H, Maar K and Staib W: The endocrine
background of human renal cell carcinoma. III Role of inhibitors of
R 5020 binding in tumour cytosol. Urol Int. 34:321–329. 1979.
View Article : Google Scholar
|
|
64
|
Bojar H, Maar K and Staib W: The endocrine
background of human renal cell carcinoma. IV Glucocorticoid
receptors as possible mediators of progestogen action. Urol Int.
34:330–338. 1979. View Article : Google Scholar
|
|
65
|
Arai Y, Nonomura N, Nakai Y, Nishimura K,
Oka D, Shiba M, Nakayama M, Takayama H, Mizutani Y, Miki T, et al:
The growth-inhibitory effects of dexamethasone on renal cell
carcinoma in vivo and in vitro. Cancer Invest. 26:35–40. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Christophersen AO, Lie AK and Fosså SD:
Unexpected 10 years complete remission after cortisone mono-therapy
in metastatic renal cell carcinoma. Acta Oncol. 45:226–228. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yakirevich E, Morris DJ, Tavares R,
Meitner PA, Lechpammer M, Noble L, de Rodriguez AF, Gomez-Sanchez
CE, Wang LJ, Sabo E, et al: Mineralocorticoid receptor and
11beta-hydroxysteroid dehydrogenase type II expression in renal
cell neoplasms: A tissue microarray and quantitative RT-PCR study.
Am J Surg Pathol. 32:874–883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
King S, Bray S, Galbraith S, Christie L
and Fleming S: Evidence for aldosterone-dependent growth of renal
cell carcinoma. Int J Exp Pathol. 95:244–250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Varela I, Tarpey P, Raine K, Huang D, Ong
CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al: Exome
sequencing identifies frequent mutation of the SWI/SNF complex gene
PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kotelevtsev Y, Brown RW, Fleming S, Kenyon
C, Edwards CR, Seckl JR and Mullins JJ: Hypertension in mice
lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest.
103:683–689. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Khan MI, Bielecka ZF, Najm MZ, Bartnik E,
Czarnecki JS, Czarnecka AM and Szczylik C: Vitamin D receptor gene
polymorphisms in breast and renal cancer: Current state and future
approaches (Review). Int J Oncol. 44:349–363. 2014.
|
|
72
|
Nagakura K, Hayakawa M, Hata M and
Nakamura H: 1,25-Dihydroxyvitamin D3 receptors and their
relationship to histological features in renal cell carcinoma. J
Urol. 137:1300–1303. 1987.PubMed/NCBI
|
|
73
|
Liu W, Tretiakova M, Kong J, Turkyilmaz M,
Li YC and Krausz T: Expression of vitamin D3 receptor in kidney
tumors. Hum Pathol. 37:1268–1278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Trydal T, Bakke A, Aksnes L and Aarskog D:
1,25-Dihydro−xyvitamin D3 receptor measurement in
primary renal cell carcinomas and autologous normal kidney tissue.
Cancer Res. 48:2458–2461. 1988.PubMed/NCBI
|
|
75
|
Madej A, Puzianowska-Kuznicka M, Tanski Z,
Nauman J and Nauman A: Vitamin D receptor binding to DNA is altered
without the change in its expression in human renal clear cell
cancer. Nephron Exp Nephrol. 93:e150–e157. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Blomberg Jensen M, Andersen CB, Nielsen
JE, Bagi P, Jørgensen A, Juul A and Leffers H: Expression of the
vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and
24-hydroxylase in the human kidney and renal clear cell cancer. J
Steroid Biochem Mol Biol. 121:376–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Langner C, Ratschek M, Rehak P, Schips L
and Zigeuner R: Steroid hormone receptor expression in renal cell
carcinoma: An immunohistochemical analysis of 182 tumors. J Urol.
171:611–614. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Fujioka T, Hasegawa M, Ishikura K,
Matsushita Y, Sato M and Tanji S: Inhibition of tumor growth and
angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J
Urol. 160:247–251. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lambert JR, Eddy VJ, Young CD, Persons KS,
Sarkar S, Kelly JA, Genova E, Lucia MS, Faller DV and Ray R: A
vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin
D3 inhibits growth of human kidney cancer cells and suppresses
tumor growth. Cancer Prev Res (Phila). 3:1596–1607. 2010.
View Article : Google Scholar
|
|
80
|
Obara W, Konda R, Akasaka S, Nakamura S,
Sugawara A and Fujioka T: Prognostic significance of vitamin D
receptor and retinoid X receptor expression in renal cell
carcinoma. J Urol. 178:1497–1503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Motzer RJ, Murphy BA, Bacik J, Schwartz
LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella
D, et al: Phase III trial of interferon alfa-2a with or without
13-cis-retinoic acid for patients with advanced renal cell
carcinoma. J Clin Oncol. 18:2972–2980. 2000.PubMed/NCBI
|
|
82
|
Atzpodien J, Kirchner H, Jonas U, Bergmann
L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller
SC, et al; Prospectively Randomized Trial of the German Cooperative
Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2-
and interferon alfa-2a-based immunochemotherapy in advanced renal
cell carcinoma: A Prospectively Randomized Trial of the German
Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J
Clin Oncol. 22:1188–1194. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li JJ, Li SA and Cuthbertson TL: Nuclear
retention of all steroid hormone receptor classes in the hamster
renal carcinoma. Cancer Res. 39:2647–2651. 1979.PubMed/NCBI
|
|
84
|
Vrtačnik P, Ostanek B, Mencej-Bedrač S and
Marc J: The many faces of estrogen signaling. Biochem Med Zagreb.
24:329–342. 2014. View Article : Google Scholar
|
|
85
|
Hemstreet GP III, Wittliff JL, Sarrif AM,
Hall ML III, McRae LJ and Durant JR: Comparison of steroid receptor
levels in renal-cell carcinoma and autologous normal kidney. Int J
Cancer. 26:769–775. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tickoo SK, Gopalan A, Tu JJ, Harik LR,
Al-Ahmadie HA, Fine SW, Olgac S and Reuter VE: Estrogen and
progesterone-receptor-positive stroma as a non-tumorous
proliferation in kidneys: A possible metaplastic response to
obstruction. Mod Pathol. 21:60–65. 2008. View Article : Google Scholar
|
|
87
|
Fucic A, Gamulin M, Ferencic Z, Katic J,
Krayer von Krauss M, Bartonova A and Merlo DF: Environmental
exposure to xenoestrogens and oestrogen related cancers:
Reproductive system, breast, lung, kidney, pancreas, and brain.
Environ Health. 11(Suppl 1): S82012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Adsay NV, Eble JN, Srigley JR, Jones EC
and Grignon DJ: Mixed epithelial and stromal tumor of the kidney.
Am J Surg Pathol. 24:958–970. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li SA, Liao DZ, Yazlovitskaya EM, Pantazis
CG and Li JJ: Induction of cathepsin D protein during estrogen
carcinogenesis: Possible role in estrogen-mediated kidney tubular
cell damage. Carcinogenesis. 18:1375–1380. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Jakse G and Müller-Holzner E: Hormone
receptors in renal cancer: An overview. Semin Surg Oncol.
4:161–164. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S
and Dahiya R: Estrogen receptor alpha polymorphisms and renal cell
carcinoma - a possible risk. Mol Cell Endocrinol. 202:109–116.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S
and Dahiya R: Single nucleotide polymorphisms of estrogen receptor
alpha in human renal cell carcinoma. Biochem Biophys Res Commun.
296:1200–1206. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yu CP, Ho JY, Huang YT, Cha TL, Sun GH, Yu
DS, Chang FW, Chen SP and Hsu RJ: Estrogen inhibits renal cell
carcinoma cell progression through estrogen receptor-β activation.
PLoS One. 8:e566672013. View Article : Google Scholar
|
|
94
|
Song W, Yeh CR, He D, Wang Y, Xie H, Pang
ST, Chang LS, Li L and Yeh S: Infiltrating neutrophils promote
renal cell carcinoma progression via VEGFa/HIF2α and estrogen
receptor β signals. Oncotarget. 6:19290–19304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ivantsov AO, Imianitov EN, Moiseenko VM,
Matsko DE and Artem'eva AS: Expression of Ki-67, p53, bcl-2,
estrogen receptors alpha in patients with clear cell renal
carcinoma and epidermal growth factor receptor mutation. Arkh
Patol. 73:6–7. 2011.(In Russian). PubMed/NCBI
|
|
96
|
Antonio P, Gabaldón M, Lacomba T and Juan
A: Effect of the antiestrogen nafoxidine on the occurrence of
estrogen-dependent renal tumors in hamster. Horm Metab Res.
6:522–524. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wada T, Nishiyama K, Maeda M, Hara S,
Tanaka N, Yasutomi M and Kurita T: Combined chemoendocrine
treatment with tegafur and tamoxifen for advanced renal cell
carcinoma. Anticancer Res. 15:1581–1584. 1995.PubMed/NCBI
|
|
98
|
Kimura N, Mizokami A, Oonuma T, Sasano H
and Nagura H: Immunocytochemical localization of androgen receptor
with polyclonal antibody in paraffin-embedded human tissues. J
Histochem Cytochem. 41:671–678. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Brown DF, Dababo MA, Hladik CL, Eagan KP,
White CL III and Rushing EJ: Hormone receptor immunoreactivity in
heman-gioblastomas and clear cell renal cell carcinomas. Mod
Pathol. 11:55–59. 1998.PubMed/NCBI
|
|
100
|
Putz J, Wirth MP, Froehner M and Jahn S:
Re: Zhu et al: The expression and evaluation of androgen receptor
in human renal cell carcinoma (Urology 2014;83:510.e19–24).
Urology. 84:734–735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zhu G, Liang L, Li L, Dang Q, Song W, Yeh
S, He D and Chang C: The expression and evaluation of androgen
receptor in human renal cell carcinoma. Urology. 83:510.e519–524.
2014. View Article : Google Scholar
|
|
102
|
He D, Li L, Zhu G, Liang L, Guan Z, Chang
L, Chen Y, Yeh S and Chang C: ASC-J9 suppresses renal cell
carcinoma progression by targeting an androgen receptor-dependent
HIF2α/VEGF signaling pathway. Cancer Res. 74:4420–4430. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Noronha RF and Rao BR: Increased
dihydrotestosterone receptor levels in high-stage renal
adenocarcinoma. Cancer. 56:134–137. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nakano E, Tada Y, Fujioka H, Matsuda M,
Osafune M, Kotake T, Sato B, Takaha M and Sonoda T: Hormone
receptor in renal cell carcinoma and correlation with clinical
response to endocrine therapy. J Urol. 132:240–245. 1984.PubMed/NCBI
|
|
105
|
Ahmed T, Benedetto P, Yagoda A, Watson RC,
Scher HI, Herr HW, Sogani PC, Whitmore WF and Pertschuk L:
Estrogen, progesterone, and androgen-binding sites in renal cell
carcinoma. Observations obtained in Phase II trial of flutamide.
Cancer. 54:477–481. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Liu Z and Lu Y, He Z, Chen L and Lu Y:
Expression analysis of the estrogen receptor target genes in renal
cell carcinoma. Mol Med Rep. 11:75–82. 2015.
|
